Literature DB >> 15793865

p62 Expression in primary carcinomas of the digestive system.

Hong-Liu Qian1, Xuan-Xian Peng, Shou-Hui Chen, Hui-Ming Ye, Jing-Hua Qiu.   

Abstract

AIM: To characterize p62 expression and define the relationship between p62 expression and cell proliferation in primary carcinomas of the digestive system.
METHODS: p62 expression was characterized in surgically resected tumor specimens from 60 patients with primary carcinomas of the digestive tract (including 22 esophageal carcinomas, 17 gastric carcinomas, and 21 colorectal carcinomas) and 40 patients with hepatocellular carcinoma (HCC) by immunohistochemistry (IHC). The cell proliferation was determined by IHC of Ki-67 in 40 patients with HCC.
RESULTS: Twenty-two cases of esophageal carcinoma were histopathologically diagnosed as squamous cell carcinoma. We combined the gastric and colorectal carcinomas based on the equivalent histology. The 38 tumors in the combined groups, consisted of 17 well-differentiated, eight moderately differentiated, nine poorly differentiated carcinomas, and four mucinous adenocarcinomas. According to the criteria of Edmondson and Steiner, 40 patients with HCC were graded (2 grade I, 17 grade II and 21 grade III). p62 expression in primary carcinomas of the gastrointestinal tract (60/60,100%) was higher than that (27/40, 67.5%) of HCC (P<0.01, chi(2) = 19.63). High expression levels of p62 were positively correlated with histological grades in gastric and colorectal carcinomas (P<0.0001) and inversely associated with those in HCC (P = 0.0322). No significant correlations were observed for esophageal carcinomas (P = 0.8246). p62 expression was also detected in the cytoplasm of morphologically normal columnar epithelial cells adjacent to the cancer foci of gastric and colorectal carcinomas. In 40 HCC specimens, the mean Ki-67 labeling index (LI) was (19.6+/-16.0)%. It was (28.3+/-18.73)% in 12 cases with high p62 expression (+++), (7.53+/-14.83)% in 13 cases without p62 expression(-). Patients with a high p62 expression showed a significantly higher level of Ki-67 staining than those without p62 expression (P<0.05, t = 2.069).
CONCLUSION: p62 expression is common in carcinomas of the digestive system and higher in carcinomas of the gastrointestinal tract than in primary HCC. p62 is a cellular differentiation-related protein. Cancer cells with a high p62 expression exhibited highgrowth fractions in HCC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15793865      PMCID: PMC4305875          DOI: 10.3748/wjg.v11.i12.1788

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  19 in total

Review 1.  The Ki-67 protein: from the known and the unknown.

Authors:  T Scholzen; J Gerdes
Journal:  J Cell Physiol       Date:  2000-03       Impact factor: 6.384

2.  Overexpression of an mRNA-binding protein in human colorectal cancer.

Authors:  J Ross; I Lemm; B Berberet
Journal:  Oncogene       Date:  2001-10-04       Impact factor: 9.867

3.  A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development.

Authors:  J Nielsen; J Christiansen; J Lykke-Andersen; A H Johnsen; U M Wewer; F C Nielsen
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

4.  Simple tumor profile chart based on cell kinetic parameters and histologic grade is useful for estimating the natural growth rate of hepatocellular carcinoma.

Authors:  Tomoki Nakajima; Michihisa Moriguchi; Yasuhide Mitsumoto; Tatsuo Katagishi; Hiroyuki Kimura; Hiroyuki Shintani; Takeshi Deguchi; Takeshi Okanoue; Keizo Kagawa; Tsukasa Ashihara
Journal:  Hum Pathol       Date:  2002-01       Impact factor: 3.466

5.  De-novo humoral immune responses to cancer-associated autoantigens during transition from chronic liver disease to hepatocellular carcinoma.

Authors:  J Y Zhang; W Zhu; H Imai; K Kiyosawa; E K Chan; E M Tan
Journal:  Clin Exp Immunol       Date:  2001-07       Impact factor: 4.330

Review 6.  The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues.

Authors:  S Hammarström
Journal:  Semin Cancer Biol       Date:  1999-04       Impact factor: 15.707

Review 7.  Autoantibodies to IGF-II mRNA binding protein p62 and overexpression of p62 in human hepatocellular carcinoma.

Authors:  Jianying Zhang; Edward K L Chan
Journal:  Autoimmun Rev       Date:  2002-05       Impact factor: 9.754

8.  EBAG9/RCAS1 expression in hepatocellular carcinoma: correlation with tumour dedifferentiation and proliferation.

Authors:  T Aoki; S Inoue; H Imamura; J Fukushima; S Takahashi; T Urano; K Hasegawa; T Ogushi; Y Ouchi; M Makuuchi
Journal:  Eur J Cancer       Date:  2003-07       Impact factor: 9.162

9.  Increased expression of IGF II mRNA-binding protein 1 mRNA is associated with an advanced clinical stage and poor prognosis in patients with ovarian cancer.

Authors:  Lijun Gu; Kazushi Shigemasa; Koso Ohama
Journal:  Int J Oncol       Date:  2004-03       Impact factor: 5.650

10.  Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer.

Authors:  Linda Soo Hoo; Jianying Y Zhang; Edward K L Chan
Journal:  Oncogene       Date:  2002-07-25       Impact factor: 9.867

View more
  9 in total

1.  The IGF2 mRNA binding protein p62/IGF2BP2-2 induces fatty acid elongation as a critical feature of steatosis.

Authors:  Stephan Laggai; Sonja M Kessler; Stefan Boettcher; Valérie Lebrun; Katja Gemperlein; Eva Lederer; Isabelle A Leclercq; Rolf Mueller; Rolf W Hartmann; Johannes Haybaeck; Alexandra K Kiemer
Journal:  J Lipid Res       Date:  2014-04-22       Impact factor: 5.922

2.  SQSTM1 Expression in Hepatocellular Carcinoma and Relation to Tumor Recurrence After Radiofrequency Ablation.

Authors:  Amr Abdel-Moety; Nahed Baddour; Perihan Salem; Hesham El-Tobgy; Assem El-Shendidi
Journal:  J Clin Exp Hepatol       Date:  2021-12-09

3.  YY1-MIR372-SQSTM1 regulatory axis in autophagy.

Authors:  Lifeng Feng; Yanning Ma; Jie Sun; Qi Shen; Leiming Liu; Haiqi Lu; Faliang Wang; Yongfang Yue; Jiaqiu Li; Shenjie Zhang; Xiaoying Lin; Jue Chu; Weidong Han; Xian Wang; Hongchuan Jin
Journal:  Autophagy       Date:  2014-06-11       Impact factor: 16.016

Review 4.  Of the atypical PKCs, Par-4 and p62: recent understandings of the biology and pathology of a PB1-dominated complex.

Authors:  J Moscat; M T Diaz-Meco; M W Wooten
Journal:  Cell Death Differ       Date:  2009-08-28       Impact factor: 15.828

5.  Alteration of p62/SQSTM1 Expression Is Uncommon in Gastrointestinal and Prostate Cancer Tissues.

Authors:  Eun Mi Je; Nam Jin Yoo; Sug Hyung Lee
Journal:  Gut Liver       Date:  2013-09-11       Impact factor: 4.519

6.  p62/sequestosome 1 in human colorectal carcinoma as a potent prognostic predictor associated with cell proliferation.

Authors:  Shun Nakayama; Hideaki Karasawa; Takashi Suzuki; Shinichi Yabuuchi; Kiyoshi Takagi; Takashi Aizawa; Yoshiaki Onodera; Yasuhiro Nakamura; Mika Watanabe; Fumiyoshi Fujishima; Hiroshi Yoshida; Takanori Morikawa; Tomohiko Sase; Takeshi Naitoh; Michiaki Unno; Hironobu Sasano
Journal:  Cancer Med       Date:  2017-05-23       Impact factor: 4.452

7.  YAP1 enhances cell proliferation, migration, and invasion of gastric cancer in vitro and in vivo.

Authors:  Dan Sun; Xiaoting Li; Yingjian He; Wenhui Li; Ying Wang; Huan Wang; Shanshan Jiang; Yan Xin
Journal:  Oncotarget       Date:  2016-12-06

8.  Epidemiology of Drug- and Herb-Induced Liver Injury Assessed for Causality Using the Updated RUCAM in Two Hospitals from China.

Authors:  Yongwu Chen; Chongwei Wang; Hui Yang; Ping Huang; Jiana Shi; Yongxi Tong; Jinying Jiang; Xin Zhang; Wanyuan Chen; Zixue Xuan
Journal:  Biomed Res Int       Date:  2021-02-24       Impact factor: 3.411

9.  Stable SET knockdown in head and neck squamous cell carcinoma promotes cell invasion and the mesenchymal-like phenotype in vitro, as well as necrosis, cisplatin sensitivity and lymph node metastasis in xenograft tumor models.

Authors:  Lays M Sobral; Lucas O Sousa; Ricardo D Coletta; Hamilton Cabral; Lewis J Greene; Eloiza H Tajara; J Silvio Gutkind; Carlos Curti; Andréia M Leopoldino
Journal:  Mol Cancer       Date:  2014-02-20       Impact factor: 27.401

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.